Doç.Dr. Emre BİLGİN

Doç.Dr.

Emre BİLGİN

Birim

Tıp Fakültesi

Dahili Tıp Bilimleri Bölümü

Google Orc Scopus WOS

İletişim

H-indeks (WoS)

Atıf (WoS)

H-indeks (Scopus)

Atıf (Scopus)

H-indeks (Google Scholar)

Atıf (Google Scholar)

ANAHTAR KELİMELER

rheumatoid arthritis (7)

Rheumatoid arthritis (6)

Spondyloarthritis (6)

Comorbidities (5)

Epidemiology (5)

Real-world evidence (5)

bDMARD (3)

Registries (3)

spondyloarthritis (3)

Ankylosing spondylitis (2)

biological DMARD (2)

Cancer (2)

Disease-modifying Drugs (DMARDs) (2)

familial Mediterranean fever (2)

Fever of unknown origin (2)

Gout (2)

Inflammation (2)

interstitial lung disease (2)

mortality (2)

Prognostic factors (2)

Public health (2)

real-life (2)

rheumatology (2)

Rituximab (2)

tofacitinib (2)

treatment (2)

academia (1)

Achilles tendon (1)

Adolescents (1)

adult (1)

Adult-onset Still?s disease (1)

Adult-onset Still's disease (1)

albumin (1)

Amyloidosis (1)

ANCA associated vasculitis (1)

ANCA subgroups (1)

ANCA-associated vasculitis (1)

anticitrullinated peptide (1)

Anti-citrullinated protein antibodies (1)

Anti-TNF therapy (1)

Arthralgia (1)

Arthritis (1)

artificial intelligence (1)

Autoantibody (1)

Autoimmune rheumatic diseases (1)

axial spondyloarthritis (1)

axSpA (1)

BASDAI50 (1)

Biologic (1)

Biologic agents (1)

biological therapy (1)

biological/targeted DMARDs (1)

Biomarker (1)

blood group (1)

bone spurs (1)

breast cancer (1)

cancer (1)

cancer risk (1)

Cardiovascular disease (1)

Central demyelination (1)

certolizumab (1)

challenges (1)

chest expansion (1)

child (1)

chronic kidney disease (1)

clinical trial (1)

cohort study (1)

colchicine (1)

comorbidities (1)

comorbidity (1)

Comorbidity (1)

complementary alternative medicine (1)

complete renal response (1)

congenital heart block (1)

Connective tissue disorders (1)

costotransverse (1)

costovertebral (1)

craniocervical junction (1)

Craniocervical posture (1)

Cyclophosphamide (1)

deep learning (1)

development (1)

Disease activity (1)

Disease activity score (1)

disease modifying drug (1)

Disease-modifying antirheumatic drugs (DMARDs) (1)

Education (1)

elderly (1)

enteropathic spondyloarthritis (1)

Eosinophilic granulomatosis with polyangiitis (1)

Erythrocyte sedimentation rate (1)

Familial Mediterranean fever (1)

Family (1)

ferritin (1)

Ferritin (1)

generative pre-trained transformers (GPT) (1)

geoepidemiology (1)

GLP-1 receptor agonists (1)

Granulomatous polyangiitis (1)

HBV (1)

HCV (1)

Head-neck cancers (1)

Hematologic malignancy (1)

herbal (1)

IGRA (1)

Immune checkpoint inhibitor (1)

Immune System Diseases (1)

Immunosuppressive drugs (1)

Incidence rate (1)

Infectious diseases (1)

Inflammatory arthritis (1)

Influenza (1)

Influenza-like diseases (1)

Interferon-gamma release assays (1)

Interleukin-17A (1)

inflammatory bowel disease (1)

influenza-like illness (1)

kidney biopsy (1)

large language models (LLMs) (1)

Latent tuberculosis reactivation (1)

Lung cancer (1)

Lungs (1)

lupus nephritis (1)

lymphoma (1)

machine learning (1)

manubriosternal (1)

Mepolizumab (1)

Mortality (1)

Multiple sclerosis (1)

nationwide (1)

nation-wide (1)

Natural language processing (NLP) (1)

Neighborhood (1)

neonatal lupus (1)

Obesity (1)

Observational studies/ registry (1)

opportunities (1)

Osteoarthritis (1)

outcome (1)

Outcome (1)

Outcome measures (1)

Pan-immune-inflammation value (1)

Periodontitis (1)

Physical activity (1)

PILE (1)

PIV (1)

pleuroparenchymal fibroelastosis (1)

polyarteritis nodosa (1)

predictor (1)

Prognosis (1)

prostate cancer (1)

psoriasis (1)

Psoriatic (1)

psoriatic arthritis (1)

Psoriatic arthritis (1)

Pulmonary nodules (1)

QuantiFERON-TB Gold Plus (1)

radiography (1)

Registry (1)

Relapse (1)

rescreening (1)

Respiratory syncytial virus (1)

retention rate (1)

rheumatic diseases (1)

rheumatoid factor (1)

School (1)

Social capital (1)

spondylitis (1)

Standardized incidence ratio (1)

sternoclavicular (1)

Systemic lupus erythematosus (1)

Systemic sclerosis (1)

targeted-synthetic disease modifying anti-rheumatismal drugs (1)

Temporomandibular disorders (1)

thrombocyte (1)

TNF inhibitors (1)

TReasure (1)

treatment resistance (1)

tuberculosis (1)

Tumor necrosis factor inhibitors (1)

unresponsiveness (1)

Validation (1)

Vasculitis (1)

venous thromboembolism (1)

viral hepatitis (1)

viral infection (1)

viral reactivation (1)

Akademik Görevler

Öğrenim Bilgisi

BM SÜRDÜRÜLEBİLİR KALKINMA AMAÇLARI

Sürdürülebilir Kalkınma Amaçları yoksulluğun son erdirilmesi, çevrenin korunması, iklim krizine karşı önlem alınması, refahın adil paylaşımı ve barışı hedefliyor.